First filing for Chugai's ALK contender alectinib, in Japan
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary Chugai has submitted the first approval application globally for alectinib (AF802/RG7853), seeking approval of the second-generation oral anaplastic lymphoma kinase (ALK) inhibitor in Japan for the treatment of non-small cell lung cancer (NSCLC).